Dr. Michael W. Simon, M.D.
Pediatrics (Pediatrics Physician)
At a glance
- In the NPI registry since
- 2007
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Pediatrics Physician primary
KY license 22740
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Payments from drug and device companies
In 2025, 3 companies reported 16 payments worth $532 in total to this clinician.
| Corium, LLC | $463 |
|---|---|
| Pfizer Inc. | $54.51 |
| Cipher Pharmaceuticals US LLC | $14.84 |
| Food and Beverage | $532 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 11 industry-funded studies in 2025, from 6 companies. The companies reported $169,228 in research payments for these studies, mostly to the institutions running them.
- A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults
ModernaTX, Inc. · Active, not recruiting · NCT05164094 - A Phase 2/3 Age De-escalating Study to Evaluate the Safety and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Vaccine (SARS-CoV-2 rS) With Matrix-M™ Adjuvant in Children 6 Months to < 12 Years of Age
Novavax Inc - Observational Evaluation of Atopic Dermatitis in Pediatric Patients
Sanofi US Services Inc. · Active, not recruiting · NCT03687359 - Study of Mixed Vaccination Schedules With a 21-valent Pneumococcal Conjugate Vaccine and a 20-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age
Sanofi Pasteur Inc. · Active, not recruiting · NCT06824181 - A Study on the Immunogenicity and Safety of 3 Different Dose Concentrations of a Respiratory Syncytial Virus Vaccine in Infants and Toddlers
Sanofi Pasteur Inc. · Terminated · NCT06705140 - Study of an Investigational Pentavalent Meningococcal ABCYW Vaccine in Adults and Adolescents
Sanofi Pasteur Inc. · Completed · NCT06128733 - A Study to Assess Adverse Events and Change in Symptoms With Linaclotide Versus Placebo in Pediatric Subjects, Ages 2 to 5 Years, With Functional Constipation
AbbVie Inc. · Completed · NCT05652205 - A phase 2B, randomized, observer-blinded trial to describe the safety,
GlaxoSmithKline, LLC. - A phase 2, randomized, double-blind, multi-dose, dose finding study to
GlaxoSmithKline, LLC. - Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273.214 SARS-CoV-2 (COVID-19) Vaccine in Infants
ModernaTX, Inc. · Terminated · NCT05584202
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.